Polymersomes functionalised with multiple ligands

Giuseppe Battaglia
UCL Business ltd

The present invention is directed to a nanoparticle or microparticle for binding to the surface of a cell, wherein the nanoparticle or microparticle comprises (i) multiple different ligand types on its external surface which are capable of binding to different respective receptor types on said cell surface, and (ii) a polymer brush on its external surface. The present invention is further directed to pharmaceutical compositions comprising a plurality of nanoparticles or microparticles of the invention, medical uses of such nanoparticles or microparticles, and a vaccine comprising such nanoparticles or microparticles.

Filing date: 7 Jul, 2020

WO2020144467A1

Chimeric antigen receptors specific for P95HER2 and uses thereof

Joaquín Arribas López; Irene Rius Ruiz; Macarena Romás Alonso; Alena Gros Vidal; Carlos Alberto Fajardo Calderón
VHIO

La presente invención se refiere a un receptor de antígeno quimérico (CAR) capaz de 5 dirigirse a células que expresan p95HER2. La invención también se refiere a un fragmento variable de cadena sencilla (ScFv), a un dominio de unión a antígeno y a un anticuerpo o fragmento de anticuerpo del mismo capaz de unirse al antígeno p95HER2. Además, la presente invención se refiere a un conjugado anticuerpo-fármaco (ADC) que comprende un agente terapéutico y un anticuerpo o dominio de unión a antígeno 10 específico para p95HER2. La invención también se refiere a un método de diagnóstico de cáncer y a una composición farmacéutica para su uso en un método de prevención o tratamiento del cáncer que comprenden el CAR y/o el dominio de unión a antígeno o el anticuerpo de la invención.

Filing date: 12 Jun, 2020

EP20382457.8 - PCT/EP2021/064383 - 17/999,769

Production of nanoparticles and microparticles

Giuseppe Battaglia Aroa Duro Castano
UCL Business ltd

The present invention is directed to a method for producing nanoparticles and microparticles composed of peptide- or peptoid-containing amphiphilic polymers. The method is simple, capable of achieving high yields, and can be tailored to produce a range of industrially and therapeutically useful structures including vesicles, micelles and hydrogels. The present invention also provides related hydrogels and vesicles having beneficial properties such an ability to degrade and release a payload in response to external stimuli.

Filing date: 1 May, 2020

WO2020225538A1

CD22 Targeting-moiety for the treatment of B-cell acute lymphoblastic Leukemia (B-ALL).

MENÉNDEZ BUJÁN, Mr. Pablo; VELASCO HERNÁNDEZ, Ms. Talía; ROMINA ZANETTI, Ms. Samanta; ENGEL ROCAMORA, Mr. Pablo; SÁNCHEZ MARTÍNEZ, Mr. Diego; GUTIERREZ AGÜERA, Mr. Francisco
IJC

The present invention provides therapeutics for the treatment of CD22-positive cancers such as B-cell acute lymphoblastic eukemia (B-ALL). In particular, the present invention provides an anti-CD22 monoclonal antibody whose F(AB')2, particularly the scFv fragment, can target the CD22 antigen, for use in the treatment of CD22-positive cancers.

Filing date: 11 Mar, 2020

Licenced date: 16 Jul, 2020

EP20382175.6